Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Johnson & Johnson Kick-Starts Suzhou Production

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson Medical has commenced operation at its Suzhou Industrial Park, starting off with orthopedic implants, which have been experiencing the fastest growth in the firm's portfolio. The first DePuy factory will make products related to artificial joint replacement and trauma care to fulfill 10-20 percent of the company's global output. With other localized products coming online, the Suzhou base is set to become J&J Medical's largest production facility in the next five years. There are plans to introduce minimally invasive surgical devices by the end of this year and cardiology products in 2009. China is experiencing huge domestic demand and growth for orthopedic implants; the market is expected to increase from 500 million yuan in 2007 to 2.1 billion yuan in 2015. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068318

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel